Xilio Therapeutics
Develops masked immuno-oncology therapies designed to activate within tumors.
$9.02
After-hours close−0.08 (−0.82%)
At close$9.10(+1.96%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.82 | — | — |
| Aug 2026 | −$0.59 | −$0.33 | +44.1% |
| Aug 2026 | −$0.59 | −$0.33 | +44.1% |
| May 2026 | −$0.66 | −$0.58 | +12.1% |
| Mar 2026 | −$1.68 | −$0.85 | +49.4% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Apr 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.82 | — | — | $4.8M | — | — |
| Aug 13, 2026 | −$0.59 | −$0.33 | +44.1% | $12.7M | $18.7M | +46.9% |
| Aug 12, 2026 | −$0.59 | −$0.33 | +44.1% | $12.7M | $18.7M | +46.9% |
| May 12, 2026 | −$0.66 | −$0.58 | +12.1% | $8.5M | $12.7M | +48.5% |
| Mar 23, 2026 | −$1.68 | −$0.85 | +49.4% | $10.9M | $13.7M | +25.6% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 13, 2025 | ||||||
| Aug 14, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 11, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 14, 2024 | ||||||
| Apr 1, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 2, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 1, 2022 | ||||||
| Dec 2, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||